Advertisement

Histochemical Determination of Androgen Binding Sites in Prostatic Adenocarcinoma: Clinical Correlation

  • R. J. Macchia
  • L. P. Pertschuk
  • New York Prostate Binding Site Study Group
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)

Abstract

The figure of 80% is classically quoted as the percentage of patients with advanced prostatic adenocarcinoma who respond at least initially to hormonal manipulation. At the present time there is no method of predicting whether a given patient will respond to such therapy. It is not unreasonable to hypothesize that those patients with androgen dependent tumors should have high levels of androgen binding sites. A non-immunologic histochemical method has been developed by Pertschuk (1,2,3,4,5) to measure androgen binding sites. The principal purpose of this report is to update the clinical trial we are currently conducting to determine whether or not the test can be used to predict response to hormonal manipulation.

Keywords

Prostate Cancer Hormonal Manipulation Histochemical Technique Histochemical Detection Estrogen Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    L.P. Pertschuk, D.T. Zava, E. Gaetjens, R.J. Macchia, D.J. Brigati, and D.S. Kim, Detection of androgen and estrogen receptors in human prostatic carcinoma and hyperplasia by fluorescence microscopy, Res. Comm. Path. Pharmacol. 22:427 (1978).Google Scholar
  2. 2.
    L.P. Pertschuk, D.T. Zava, E. Gaetjens, R.J. Macchia, G.J. Wise, D.S. Kim, and D.J. Brigati, Histochemistry of steroid receptors in prostatic disease, Ann. Clin. Lab. Sci. 9:225 (1979).PubMedGoogle Scholar
  3. 3.
    L.P. Pertschuk, D.T. Zava, E.H. Tobin, D.J. Brigati, E. Gaetjens, R.J. Macchia, G.J. Wise, H.S. Wax, and D.S. Kim, Histochemical detection of steroid hormone receptors in the human prostate, in: “Prostate Cancer and Hormone Receptors,” G.P. Murphy and A.A. Sandberg, eds., Alan R. Liss, Inc., New York (1979).Google Scholar
  4. 4.
    L.P. Pertschuk, E.H. Tobin, P. Tanapat, E. Gaetjens, A.C. Carter, N.D. Bloom, R.J. Macchia, and K.B. Eisenberg, Histochemical analyses of steroid hormone receptors in breast and prostatic carcinoma, J. Histochem. Cytochem. 28:799 (1980).PubMedCrossRefGoogle Scholar
  5. 5.
    L.P. Pertschuk, H.E. Rosenthal, R.J. Macchia, K.B. Eisenberg, J.G. Feldman, S.H. Wax, D.S. Kim, W.F. Whitmore, Jr., J.I. Abrahams, E. Gaetjens, G.J. Wise, H.W. Herr, J.P. Karr, G.P. Murphy, and A.A. Sandberg, Correlation of histochemical and biochemical analyses of androgen binding in prostatic cancer: relation to therapeutic response, Cancer, in press.Google Scholar
  6. 6.
    J.D. Schmidt, D.E. Johnson, W.W. Scott, R.P. Gibbons, G.R. Prout, Jr., and G.P. Murphy, Chemotherapy of advanced prostatic cancer, evaluation of response parameters, Urology 7:602 (1976).PubMedCrossRefGoogle Scholar
  7. 7.
    E. Gaetjens and L.P. Pertschuk, Synthesis of fluorescent labeled-steroid hormone albumin conjugates for the histochemical detection of hormone receptors, J. Steroid Biochem. 13:1121 (1980).PubMedCrossRefGoogle Scholar
  8. 8.
    D.R. Gleason, Histologic grading and clinical staging of prostatic carcinoma, in: “Urologic Pathology: The Prostate,” M. Tannenbaum, ed., Lea and Febiger, Philadelphia (1977).Google Scholar
  9. 9.
    R.J. Boxer, Adenocarcinoma of the prostate gland, Urol. Surv. 27:75 (1977).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • R. J. Macchia
    • 1
  • L. P. Pertschuk
    • 1
  • New York Prostate Binding Site Study Group
    • 1
  1. 1.Downstate Medical SchoolNew YorkUSA

Personalised recommendations